Multi-modal strategies for overcoming tumor drug resistance: Hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology

被引:109
作者
Milane, Lara [1 ]
Ganesh, Shanthi [1 ]
Shah, Shruti [1 ]
Duan, Zhen-feng [2 ]
Amiji, Mansoor [1 ]
机构
[1] Northeastern Univ, Sch Pharm, Dept Pharmaceut Sci, Boston, MA 02115 USA
[2] Massachusetts Gen Hosp, Ctr Sarcoma & Connect Tissue Oncol, Sarcoma Biol Lab, Boston, MA 02114 USA
关键词
Tumor hypoxia; Warburg's effect; Multidrug resistance; Cancer-initiating (stem) cells; Multifunctional nanoparticles; IN-VIVO REVERSAL; MULTIDRUG-RESISTANCE; CANCER-CELLS; P-GLYCOPROTEIN; BREAST-CANCER; TARGETED DELIVERY; RNA INTERFERENCE; GENE DELIVERY; SOLID TUMOR; GLUCOSYLCERAMIDE SYNTHASE;
D O I
10.1016/j.jconrel.2011.03.032
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Inefficiencies in systemic drug delivery and tumor residence as well as micro-environmental selection pressures contribute to the development of multidrug resistance (MDR) in cancer. Characteristics of MDR include abnormal vasculature, regions of hypoxia, up-regulation of ABC-transporters, aerobic glycolysis, and an elevated apoptotic threshold. Nano-sized delivery vehicles are ideal for treating MDR cancer as they can improve the therapeutic index of drugs and they can be engineered to achieve multifunctional parameters. The multifunctional ability of nanocarriers makes them more adept at treating heterogeneous tumor mass than traditional chemotherapy. Nanocarriers also have preferential tumor accumulation via the EPR effect; this accumulation can be further enhanced by actively targeting the biological profile of MDR cells. Perhaps the most significant benefit of using nanocarrier drug delivery to treat MDR cancer is that nanocarrier delivery diverts the effects of ABC-transporter mediated drug efflux; which is the primary mechanism of MDR. This review discusses the capabilities, applications, and examples of multifunctional nanocarriers for the treatment of MDR. This review emphasizes multifunctional nanocarriers that enhance drug delivery efficiency, the application of RNAi, modulation of the tumor apoptotic threshold, and physical approaches to overcome MDR. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:237 / 247
页数:11
相关论文
共 126 条
  • [21] Glycosyl and polyalcoholic prodrugs of lonidamine
    Giorgioni, G.
    Ruggieri, S.
    Di Stefano, A.
    Sozio, P.
    Cinque, B.
    Di Marzio, L.
    Santoni, G.
    Claudi, F.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (07) : 2445 - 2450
  • [22] Multidrug resistance in cancer: Role of ATP-dependent transporters
    Gottesman, MM
    Fojo, T
    Bates, SE
    [J]. NATURE REVIEWS CANCER, 2002, 2 (01) : 48 - 58
  • [23] Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs
    Gouazé, V
    Liu, YY
    Prickett, CS
    Yu, JY
    Giuliano, AE
    Cabot, MC
    [J]. CANCER RESEARCH, 2005, 65 (09) : 3861 - 3867
  • [24] Gregory Richard I., 2006, V342, P33, DOI 10.1385/1-59745-123-1:33
  • [25] Ceramide and cell death receptor clustering
    Gulbins, E
    Grassmé, H
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2002, 1585 (2-3): : 139 - 145
  • [26] The hypoxic core: a possible answer to the cancer paradox
    Guppy, M
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 299 (04) : 676 - 680
  • [27] Modelling the molecular circuitry of cancer
    Hahn, WC
    Weinberg, RA
    [J]. NATURE REVIEWS CANCER, 2002, 2 (05) : 331 - 341
  • [28] HAMADA H, 1990, CANCER RES, V50, P3167
  • [29] Designing PEGylated therapeutic molecules: advantages in ADMET properties
    Hamidi, Mehrdad
    Rafiei, Pedram
    Azadi, Amir
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (11) : 1293 - 1307
  • [30] Pharmacokinetic consequences of pegylation
    Hamidi, Mehrdad
    Azadi, Amir
    Rafiei, Pedram
    [J]. DRUG DELIVERY, 2006, 13 (06) : 399 - 409